# Penguin Solutions, Inc.: financial statements, quarterly

PENG · Nasdaq · CIK 1616533 · [Technology](/sectors/technology.md) · fiscal year ends Aug 29

Pages: [Overview](/companies/peng.md) · [Financials](/companies/peng/financials.md) · [Filings](/companies/peng/filings.md) · [Insiders](/companies/peng/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/peng/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-12-01) | Q2 FY2024 (2024-03-01) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-30) | Q1 FY2025 (2024-11-29) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-30) | Q4 FY2025 (2025-08-29) | Q1 FY2026 (2025-11-28) | Q2 FY2026 (2026-02-27) | Q3 FY2026 (2026-05-29) | Q4 FY2026 (2026-08-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [274](/filings/0001616533-25-000061.md) | [285](/filings/0001616533-25-000061.md) | [301](/filings/0001616533-25-000061.md) | [311](/filings/0001616533-25-000061.md) | [341](/filings/0001616533-26-000050.md) | [366](/filings/0001616533-26-000050.md) | [324](/filings/0001616533-26-000050.md) | [338](/filings/0001616533-26-000050.md) | [343](/filings/0001616533-26-000050.md) | [343](/filings/0001616533-26-000050.md) | [479](/filings/0001616533-26-000050.md) | [567](/filings/0001616533-26-000050.md) |
| Cost of revenue | $m | [191](/filings/0001628280-25-000944.md) | [203](/filings/0001628280-25-016182.md) | [212](/filings/0001628280-25-034541.md) | [224 d](/filings/0001616533-26-000050.md) | [243](/filings/0001616533-26-000010.md) | [261](/filings/0001616533-26-000030.md) | [229](/filings/0001616533-26-000043.md) | [241 d](/filings/0001616533-26-000050.md) | [247](/filings/0001616533-26-000010.md) | [249](/filings/0001616533-26-000030.md) | [345](/filings/0001616533-26-000043.md) | [411 d](/filings/0001616533-26-000050.md) |
| Gross profit | $m | [82.9](/filings/0001616533-25-000061.md) | [81.9](/filings/0001616533-25-000061.md) | [88.9](/filings/0001616533-25-000061.md) | [87.1](/filings/0001616533-25-000061.md) | [97.8](/filings/0001616533-26-000050.md) | [105](/filings/0001616533-26-000050.md) | [95.1](/filings/0001616533-26-000050.md) | [96.7](/filings/0001616533-26-000050.md) | [96.1](/filings/0001616533-26-000050.md) | [93.7](/filings/0001616533-26-000050.md) | [133](/filings/0001616533-26-000050.md) | [156](/filings/0001616533-26-000050.md) |
| Research and development | $m | [21.4](/filings/0001628280-25-000944.md) | [20.5](/filings/0001628280-25-016182.md) | [19.7](/filings/0001628280-25-034541.md) | [19.9 d](/filings/0001616533-26-000050.md) | [19.8](/filings/0001616533-26-000010.md) | [19.9](/filings/0001616533-26-000030.md) | [20.2](/filings/0001616533-26-000043.md) | [19.9 d](/filings/0001616533-26-000050.md) | [18.7](/filings/0001616533-26-000010.md) | [19.0](/filings/0001616533-26-000030.md) | [22.0](/filings/0001616533-26-000043.md) | [22.0 d](/filings/0001616533-26-000050.md) |
| Selling, general and administrative | $m | [57.2](/filings/0001628280-25-000944.md) | [61.4](/filings/0001628280-25-016182.md) | [57.2](/filings/0001628280-25-034541.md) | [58.0 d](/filings/0001616533-26-000050.md) | [60.5](/filings/0001616533-26-000010.md) | [59.3](/filings/0001616533-26-000030.md) | [59.7](/filings/0001616533-26-000043.md) | [58.6 d](/filings/0001616533-26-000050.md) | [53.1](/filings/0001616533-26-000010.md) | [48.0](/filings/0001616533-26-000030.md) | [59.4](/filings/0001616533-26-000043.md) | [59.9 d](/filings/0001616533-26-000050.md) |
| Operating income | $m | [1.3](/filings/0001616533-25-000061.md) | [(3.3)](/filings/0001616533-25-000061.md) | [11.5](/filings/0001616533-25-000061.md) | [8.8](/filings/0001616533-25-000061.md) | [17.4](/filings/0001616533-26-000050.md) | [18.5](/filings/0001616533-26-000050.md) | [9.8](/filings/0001616533-26-000050.md) | [12.4](/filings/0001616533-26-000050.md) | [19.6](/filings/0001616533-26-000050.md) | [25.7](/filings/0001616533-26-000050.md) | [50.9](/filings/0001616533-26-000050.md) | [69.5](/filings/0001616533-26-000050.md) |
| Income tax | $m | [3.5](/filings/0001628280-25-000944.md) | [2.2](/filings/0001628280-25-016182.md) | [(1.3)](/filings/0001628280-25-034541.md) | [6.2 d](/filings/0001616533-26-000050.md) | [6.4](/filings/0001616533-26-000010.md) | [7.6](/filings/0001616533-26-000030.md) | [7.3](/filings/0001616533-26-000043.md) | [(1.2) d](/filings/0001616533-26-000050.md) | [1.8](/filings/0001616533-26-000010.md) | [14.4](/filings/0001616533-26-000030.md) | [7.5](/filings/0001616533-26-000043.md) | [(57.6) d](/filings/0001616533-26-000050.md) |
| Net income | $m | [(19.9)](/filings/0001628280-25-000944.md) | [(13.6)](/filings/0001628280-25-016182.md) | [5.6](/filings/0001628280-25-034541.md) | [(24.5) d](/filings/0001616533-26-000050.md) | [5.2](/filings/0001616533-26-000010.md) | [8.1](/filings/0001616533-26-000030.md) | [2.7](/filings/0001616533-26-000043.md) | [9.4 d](/filings/0001616533-26-000050.md) | [5.3](/filings/0001616533-26-000010.md) | [37.5](/filings/0001616533-26-000030.md) | [44.7](/filings/0001616533-26-000043.md) | [93.2 d](/filings/0001616533-26-000050.md) |
| Diluted EPS | $ per share | [(0.38)](/filings/0001628280-25-000944.md) | [(0.26)](/filings/0001628280-25-016182.md) | [0.10](/filings/0001628280-25-034541.md) | not reported | [0.10](/filings/0001616533-26-000010.md) | [0.09](/filings/0001616533-26-000030.md) | [(0.01)](/filings/0001616533-26-000043.md) | not reported | [0.04](/filings/0001616533-26-000010.md) | [0.58](/filings/0001616533-26-000030.md) | [0.68](/filings/0001616533-26-000043.md) | not reported |
| Basic EPS | $ per share | [(0.38)](/filings/0001628280-25-000944.md) | [(0.26)](/filings/0001628280-25-016182.md) | [0.11](/filings/0001628280-25-034541.md) | not reported | [0.10](/filings/0001616533-26-000010.md) | [0.09](/filings/0001616533-26-000030.md) | [(0.01)](/filings/0001616533-26-000043.md) | not reported | [0.04](/filings/0001616533-26-000010.md) | [0.59](/filings/0001616533-26-000030.md) | [0.73](/filings/0001616533-26-000043.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-12-01) | Q2 FY2024 (2024-03-01) | Q3 FY2024 (2024-05-31) | FY2024 (2024-08-30) | Q1 FY2025 (2024-11-29) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-30) | FY2025 (2025-08-29) | Q1 FY2026 (2025-11-28) | Q2 FY2026 (2026-02-27) | Q3 FY2026 (2026-05-29) | FY2026 (2026-08-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [529](/filings/0001628280-24-000961.md) | [442](/filings/0001628280-24-015494.md) | [454](/filings/0001628280-24-031519.md) | [383](/filings/0001616533-25-000061.md) | [370](/filings/0001628280-25-000944.md) | [622](/filings/0001628280-25-016182.md) | [710](/filings/0001628280-25-034541.md) | [454](/filings/0001616533-26-000050.md) | [461](/filings/0001616533-26-000010.md) | [489](/filings/0001616533-26-000030.md) | [440](/filings/0001616533-26-000043.md) | [647](/filings/0001616533-26-000050.md) |
| Current assets | $m | [987](/filings/0001628280-24-000961.md) | [885](/filings/0001628280-24-015494.md) | [942](/filings/0001628280-24-031519.md) | [868](/filings/0001616533-25-000061.md) | [996](/filings/0001628280-25-000944.md) | [1,245](/filings/0001628280-25-016182.md) | [1,250](/filings/0001628280-25-034541.md) | [1,064](/filings/0001616533-26-000050.md) | [1,067](/filings/0001616533-26-000010.md) | [1,238](/filings/0001616533-26-000030.md) | [1,729](/filings/0001616533-26-000043.md) | [2,249](/filings/0001616533-26-000050.md) |
| Total assets | $m | [1,631](/filings/0001628280-24-000961.md) | [1,517](/filings/0001628280-24-015494.md) | [1,546](/filings/0001628280-24-031519.md) | [1,475](/filings/0001616533-25-000061.md) | [1,583](/filings/0001628280-25-000944.md) | [1,811](/filings/0001628280-25-016182.md) | [1,803](/filings/0001628280-25-034541.md) | [1,617](/filings/0001616533-26-000050.md) | [1,598](/filings/0001616533-26-000010.md) | [1,750](/filings/0001616533-26-000030.md) | [2,191](/filings/0001616533-26-000043.md) | [2,778](/filings/0001616533-26-000050.md) |
| Current liabilities | $m | [369](/filings/0001628280-24-000961.md) | [268](/filings/0001628280-24-015494.md) | [351](/filings/0001628280-24-031519.md) | [328](/filings/0001616533-25-000061.md) | [427](/filings/0001628280-25-000944.md) | [474](/filings/0001628280-25-016182.md) | [477](/filings/0001628280-25-034541.md) | [474](/filings/0001616533-26-000050.md) | [458](/filings/0001616533-26-000010.md) | [591](/filings/0001616533-26-000030.md) | [1,120](/filings/0001616533-26-000043.md) | [1,196](/filings/0001616533-26-000050.md) |
| Total liabilities | $m | [1,215](/filings/0001628280-24-000961.md) | [1,106](/filings/0001628280-24-015494.md) | [1,116](/filings/0001628280-24-031519.md) | [1,075](/filings/0001616533-25-000061.md) | [1,174](/filings/0001628280-25-000944.md) | [1,199](/filings/0001628280-25-016182.md) | [1,208](/filings/0001628280-25-034541.md) | [1,009](/filings/0001616533-26-000050.md) | [994](/filings/0001616533-26-000010.md) | [1,139](/filings/0001616533-26-000030.md) | [1,535](/filings/0001616533-26-000043.md) | [2,038](/filings/0001616533-26-000050.md) |
| Long-term debt | $m | [748](/filings/0001628280-24-000961.md) | [741](/filings/0001628280-24-015494.md) | [667](/filings/0001628280-24-031519.md) | [657](/filings/0001616533-25-000061.md) | [658](/filings/0001628280-25-000944.md) | [639](/filings/0001628280-25-016182.md) | [640](/filings/0001628280-25-034541.md) | [442](/filings/0001616533-26-000050.md) | [442](/filings/0001616533-26-000010.md) | [443](/filings/0001616533-26-000030.md) | [295](/filings/0001616533-26-000043.md) | [736](/filings/0001616533-26-000050.md) |
| Current portion of debt | $m | [28.5](/filings/0001628280-24-000961.md) | [0.0](/filings/0001628280-24-015494.md) | [0.0](/filings/0001628280-24-031519.md) | [0.0](/filings/0001616533-25-000061.md) | [0.0](/filings/0001628280-25-000944.md) | [19.9](/filings/0001628280-25-016182.md) | [19.9](/filings/0001628280-25-034541.md) | [19.9](/filings/0001616533-26-000050.md) | [20.0](/filings/0001616533-26-000010.md) | [0.0](/filings/0001616533-26-000030.md) | [148](/filings/0001616533-26-000043.md) | [53.4](/filings/0001616533-26-000050.md) |
| Shareholders' equity | $m | [410](/filings/0001628280-24-000961.md) | [405](/filings/0001628280-24-015494.md) | [423](/filings/0001628280-24-031519.md) | [391](/filings/0001616533-25-000061.md) | [400](/filings/0001628280-25-000944.md) | [603](/filings/0001628280-25-016182.md) | [585](/filings/0001628280-25-034541.md) | [394](/filings/0001616533-26-000050.md) | [390](/filings/0001616533-26-000010.md) | [395](/filings/0001616533-26-000030.md) | [439](/filings/0001616533-26-000043.md) | [521](/filings/0001616533-26-000050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-12-01) | Q2 FY2024 (2024-03-01) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-30) | Q1 FY2025 (2024-11-29) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-30) | Q4 FY2025 (2025-08-29) | Q1 FY2026 (2025-11-28) | Q2 FY2026 (2026-02-27) | Q3 FY2026 (2026-05-29) | Q4 FY2026 (2026-08-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [31.5](/filings/0001628280-25-000944.md) | [(21.9) d](/filings/0001628280-25-016182.md) | [79.8 d](/filings/0001628280-25-034541.md) | [(12.2) d](/filings/0001616533-26-000050.md) | [13.8](/filings/0001616533-26-000010.md) | [72.9 d](/filings/0001616533-26-000030.md) | [92.8 d](/filings/0001616533-26-000043.md) | [(70.4) d](/filings/0001616533-26-000050.md) | [31.1](/filings/0001616533-26-000010.md) | [55.0 d](/filings/0001616533-26-000030.md) | [(74.8) d](/filings/0001616533-26-000043.md) | [(163) d](/filings/0001616533-26-000050.md) |
| Capital expenditure | $m | [4.6](/filings/0001628280-25-000944.md) | [5.2 d](/filings/0001628280-25-016182.md) | [3.8 d](/filings/0001628280-25-034541.md) | [5.8 d](/filings/0001616533-26-000050.md) | [1.8](/filings/0001616533-26-000010.md) | [2.3 d](/filings/0001616533-26-000030.md) | [1.9 d](/filings/0001616533-26-000043.md) | [2.9 d](/filings/0001616533-26-000050.md) | [2.9](/filings/0001616533-26-000010.md) | [1.6 d](/filings/0001616533-26-000030.md) | [2.8 d](/filings/0001616533-26-000043.md) | [4.3 d](/filings/0001616533-26-000050.md) |
| Share repurchases | $m | [13.1](/filings/0001628280-25-000944.md) | [2.7 d](/filings/0001628280-25-016182.md) | [2.1 d](/filings/0001628280-25-034541.md) | [3.3 d](/filings/0001616533-26-000050.md) | [11.1](/filings/0001616533-26-000010.md) | [6.5 d](/filings/0001616533-26-000030.md) | [31.6 d](/filings/0001616533-26-000043.md) | [3.1 d](/filings/0001616533-26-000050.md) | [20.2](/filings/0001616533-26-000010.md) | [36.9 d](/filings/0001616533-26-000030.md) | [11.8 d](/filings/0001616533-26-000043.md) | [5.5 d](/filings/0001616533-26-000050.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2024 (2023-12-01) | Q2 FY2024 (2024-03-01) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-30) | Q1 FY2025 (2024-11-29) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-30) | Q4 FY2025 (2025-08-29) | Q1 FY2026 (2025-11-28) | Q2 FY2026 (2026-02-27) | Q3 FY2026 (2026-05-29) | Q4 FY2026 (2026-08-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [52.1](/filings/0001616533-25-000061.md) | [52.0](/filings/0001616533-25-000061.md) | [54.3](/filings/0001616533-25-000061.md) | [53.1](/filings/0001616533-25-000061.md) | [54.3](/filings/0001616533-26-000050.md) | [54.4](/filings/0001616533-26-000050.md) | [53.7](/filings/0001616533-26-000050.md) | [54.4](/filings/0001616533-26-000050.md) | [55.0](/filings/0001616533-26-000050.md) | [53.2](/filings/0001616533-26-000050.md) | [55.1](/filings/0001616533-26-000050.md) | [64.0](/filings/0001616533-26-000050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 60,241,423 at 2026-10-14, from the cover of the [10-K filed 2026-10-20](/filings/0001616533-26-000050.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.